Treatment of hepatitis delta virus infection
AssigneeEIT Pharma, Inc.
InventorsDavid A. Cory, Ingrid Choong, Jeffrey S. Glenn
Life of this patent
Estimating the term…
Abstract
Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
Claims20
A method of treating a human patient having a hepatitis delta virus (HDV) infection, the method comprising administering to the patient a therapeutically effective dose of lonafarnib and a therapeutically effective dose of ritonavir.
A method of inducing immune reactivation in a human patient having a hepatitis delta virus (HDV) infection, the method comprising administering to the patient a therapeutically effective does of lonafarnib and a therapeutically effective dose of ritonavir for at least a period of time until immune reactivation is observed in the patient.
A method of treating a subject having a hepatitis delta virus (HDV) infection, the method comprising administering to the subject lonafarnib and ritonavir in amounts that result in a serum lonafarnib concentration in the subject greater than 2,000 ng/mL, or greater than 4,000 ng/mL, or in a range from 3,500 ng/mL to 7,500 ng/mL.
Dependencies are inferred from the claim text.